

# Glycogen Synthase Kinase 3 (GSK3) inhibitor - Pipeline Insight, 2022

<https://marketpublishers.com/r/G6563B34620EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: G6563B34620EN

## Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Glycogen Synthase Kinase 3 (GSK3) Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Glycogen Synthase Kinase 3 (GSK3) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Glycogen Synthase Kinase 3 (GSK3) Inhibitor Understanding

#### Glycogen Synthase Kinase 3 (GSK3) Inhibitor: Overview

Glycogen synthase kinase 3 (GSK3) is a protein kinase that phosphorylates and inhibits glycogen synthase, the enzyme that catalyzes the transfer of glucose from UDPG to glycogen. Glycogen-synthase kinase-3 (GSK3) exists in two isoforms, termed  $\alpha$  and  $\beta$ , which are generated from distinct genes. GSK3 is active in its basal state and is inhibited upon phosphorylation at Ser9 in GSK-3 $\alpha$  and at Ser21 in GSK3 $\beta$ . GSK3 is a multifunctional protein kinase and has a broad range of substrates including signaling and structural proteins, as well as transcription factors. It is involved in various key biological processes, including glucose regulation, apoptosis, protein synthesis, cell

signaling, cellular transport, gene transcription, proliferation, and intracellular communication. Accordingly, GSK-3 has been implicated in a wide variety of diseases and therefore specifically targeted for both therapeutic and imaging applications.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Glycogen Synthase Kinase 3 (GSK3) Inhibitor R&D. The therapies under development are focused on novel approaches for Glycogen Synthase Kinase 3 (GSK3) Inhibitor.

## Glycogen Synthase Kinase 3 (GSK3) Inhibitor Emerging Drugs Chapters

This segment of the Glycogen Synthase Kinase 3 (GSK3) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Glycogen Synthase Kinase 3 (GSK3) Inhibitor Emerging Drugs

### Tideglusib: AMO Pharma

Tideglusib is an orally available, small-molecule drug of the thiadiazolidinone class. It acts as an inhibitor of glycogen synthase kinase 3 (GSK3- $\alpha$ ), a widely studied tau kinase. Tideglusib is a non-ATP competitive inhibitor of glycogen synthase kinase 3 $\beta$  (GSK3 $\beta$ ) and has neuroprotective effects. The drug is currently under clinical investigation for the treatment of congenital myotonic dystrophy and progressive supranuclear palsy.

### 9 ING 41: Actuate Therapeutics

9-ING-41 is a first-in-class, intravenously administered, maleimide-based small molecule potent selective GSK-3 $\alpha$  inhibitor with significant pre-clinical antitumor activity. 9-ING-41 has significant in vitro and in vivo activity as a single agent and/or in combination with standard cytotoxic chemotherapies in a spectrum of solid tumors and

hematological malignancies including bladder, breast, glioblastoma, neuroblastoma, pancreatic, sarcomas, and renal cancers as well as lymphomas. 9-ING-41 is more selective for GSK-3 $\beta$  than for other 320 related kinases when tested in a kinase screen.

Further product details are provided in the report.....

## Glycogen Synthase Kinase 3 (GSK3) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Glycogen Synthase Kinase 3 (GSK3) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

### Major Players working on Glycogen Synthase Kinase 3 (GSK3) Inhibitor

There are approx. 8+ key companies which are developing the Glycogen Synthase Kinase 3 (GSK3) Inhibitor. The companies which have their Glycogen Synthase Kinase 3 (GSK3) Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, AMO Pharma.

### Phases

DelveInsight's report covers around 8+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Glycogen Synthase Kinase 3 (GSK3) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

### Glycogen Synthase Kinase 3 (GSK3) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Glycogen Synthase Kinase 3 (GSK3) Inhibitor therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glycogen Synthase Kinase 3 (GSK3) Inhibitor drugs.

### Glycogen Synthase Kinase 3 (GSK3) Inhibitor Report Insights

- Glycogen Synthase Kinase 3 (GSK3) Inhibitor Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

### Glycogen Synthase Kinase 3 (GSK3) Inhibitor Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

## Key Questions

### Current Scenario and Emerging Therapies:

How many companies are developing Glycogen Synthase Kinase 3 (GSK3) Inhibitor drugs?

How many Glycogen Synthase Kinase 3 (GSK3) Inhibitor drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Glycogen Synthase Kinase 3 (GSK3) Inhibitor?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glycogen Synthase Kinase 3 (GSK3) Inhibitor therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Glycogen Synthase Kinase 3 (GSK3) Inhibitor and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

AMO Pharma

Actuate Therapeutics

Rock Creek Pharmaceuticals

BCN Biosciences

HitGen

## Key Products

Tideglusib

9 ING 41

Anatabine

BCN-057

Research program: glycogen synthase kinase 3 beta inhibitors

## Contents

Introduction

Executive Summary

Glycogen Synthase Kinase 3 (GSK3) Inhibitor: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Glycogen Synthase Kinase 3 (GSK3) Inhibitor – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Glycogen Synthase Kinase 3 (GSK3) Inhibitor companies' collaborations, Licensing, Acquisition -Deal Value Trends

Glycogen Synthase Kinase 3 (GSK3) Inhibitor Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Tideglusib: AMO Pharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

### **9 ING 41: ACTUATE THERAPEUTICS**

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....



## Early Stage Products (Phase I)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

## Pre-clinical and Discovery Stage Products

Comparative Analysis

BCN-057 BCN Biosciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

## Inactive Products

Comparative Analysis

Glycogen Synthase Kinase 3 (GSK3) Inhibitor Key Companies

Glycogen Synthase Kinase 3 (GSK3) Inhibitor Key Products

Glycogen Synthase Kinase 3 (GSK3) Inhibitor- Unmet Needs

Glycogen Synthase Kinase 3 (GSK3) Inhibitor- Market Drivers and Barriers

Glycogen Synthase Kinase 3 (GSK3) Inhibitor- Future Perspectives and Conclusion

Glycogen Synthase Kinase 3 (GSK3) Inhibitor Analyst Views

Glycogen Synthase Kinase 3 (GSK3) Inhibitor Key Companies

Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Glycogen Synthase Kinase 3 (GSK3) Inhibitor

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Glycogen Synthase Kinase 3 (GSK3) Inhibitor

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Glycogen Synthase Kinase 3 (GSK3) inhibitor - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/G6563B34620EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6563B34620EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970